Brief: Adamis Provides Update On Clinical Trial Start-Up Progress For Tempol In The Treatment Of Covid-19
11/06/2021 13:43
June 11 (Reuters) - Adamis Pharmaceuticals Corp ADMP.O :
* ADAMIS PROVIDES UPDATE ON CLINICAL TRIAL START-UP PROGRESS
FOR
TEMPOL IN THE TREATMENT OF COVID-19
* ADAMIS PHARMACEUTICALS - CLINICAL TRIAL START-UP
ACTIVITIES ARE
UNDERWAY FOR EXAMINING EFFECTS OF TEMPOL IN TREATMENT OF
COVID-19
Source text for Eikon: ID:nGNX93P6m7
Further company coverage: ADMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update